检索结果-南通市图书馆

Science china(Life Sciences) 2009年第12期52卷 1192-1197页

作者： ZHAO HaiPing1,2, ZHAO YanLing1, WANG JiaBo1, LI HanBing1,2, REN YongShen1,2, ZHOU CanPing1,3, YAN Dan1 & XIAO XiaoHe1· 1 china Military Institute of chinese Materia Medica, 302 Military Hospital, Beijing 100039, china 2 Chengdu university of Traditional chinese medicine, Chengdu 610075, china 3 hunan university of chinese medicine, changsha 410208, china china Military Institute of chinese Materia Medica 302 Military Hospital Beijing China Chengdu university of Traditional chinese medicine Chengdu China hunan university of chinese medicine Changsha China

In this study, objective differences between the Cold (Han) and Hot (Re) nature of traditional chinese medicines, e.g. Strobal and Rhubarb, are determined by using a cold/hot plate differentiation technology. A novel, self-designed cold/hot plate differentiating instrument, with methodological study, was used to investigate the intervention of Strobal and Rhubarb on the temperature tropism of mice. Compared with the ICR and BALB/c mice, it was found that KM mice on the cold/hot plate were more sensitive to the change of temperature, within the tolerant temperature range of 15-40 ℃ . The temperature tropism behavior of mice is influenced by treatment with Rhubarb and Strobal, as is the activity of ATPase in liver tissue. These trends are consistent with the definition of the Cold/Hot nature of chinese medicines based on traditional chinese medicinal theory. This study showed that the differences of the Cold/Hot nature of traditional chinese medicines. might be objectively represented by the temperature tropism of animal by means of cold/hot differentiating assay.

关键词： Rhubarb Strobal Cold/Hot nature of chinese medicines cold/hot plate differentiating assay

Clinical practice guidelines for nutritional assessment and monitoring of adult ICU patients in china

在线全文

学校读者我要写书评

暂无评论

Journal of Intensive medicine 2024年第2期4卷 137-159页

作者： Xiangdong Guan Dechang Chen Yuan Xu chinese Society of Critical Care medicine Department of Critical Care medicine The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina Department of Critical Care medicine Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina Department of Critical Care medicine Beijing Tsinghua Changgung HospitalBeijingChina 不详

The chinese Society of Critical Care medicine(CSCCM)has developed clinical practice guidelines for nutrition assessment and monitoring for patients in adult intensive care units(ICUs)in *** guideline focuses on nutrition evaluation and metabolic monitoring to achieve optimal and personalized nutrition therapy for critically ill *** guideline was developed by experts in critical care medicine and evidence-based medicine methodology and was developed after a thorough review of the system and a summary of relevant trials or studies published from 2000 to July 2023.A total of 18 recommendations were formed and consensus was reached through discussions and reviews by expert groups in critical care medicine,parenteral and enteral nutrition,and *** recommendations are based on currently available evidence and cover several key fields,including screening and assessment,evaluation and assessment of enteral feeding intolerance,metabolic and nutritional measurement and monitoring during nutrition therapy,and organ function evaluation related to nutrition *** question was analyzed according to the Population,Intervention,Comparison,and Outcome(PICO)*** addition,interpretations were provided for four questions that did not reach a consensus but may have potential clinical and research *** plan is to update this nutrition assessment and monitoring guideline using the international guideline update method within 3–5 years.

关键词： Adults Critical illness Intensive care unit Nutriti on Nutriti on assessment and monitoring Guideline Recommendations chinese Society of Critical Care medicine-chinese Medical Association(CSCCM-CMA)

chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations(2023 edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Medical Journal 2024年第9期137卷 1016-1018页

作者： The Society of Cancer Precision medicine of chinese Anti-Cancer Association The Lung Cancer Expert Group of chinese Medical Association Publishing House Baohui Han Hua Zhong 不详 Department of Respiratory medicine Shanghai Chest HospitalSchool of MedicineShanghai JiaoTong UniversityShanghai 20030China Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)***,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing *** this context,chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the Society of Cancer Precision medicine of chinese Anti-Cancer Association and the Lung Cancer Expert Group of chinese Medical Journals,aiming to provide standardized treatment guidance for clinical practice.

关键词： immunotherapy cancer lung

Clinical Management Guidelines for Intrahepatic Cholestasis of Pregnancy

在线全文

学校读者我要写书评

暂无评论

Maternal-Fetal medicine 2024年第1期6卷 13-22页

作者： Obstetrics Group of the Gynecology and Obstetrics Branch of chinese Medical Association Perinatal medicine Branch of chinese Medical Association Xinyang Yu Huixia Yang Hongbo Qi 不详 Medical university Chongqing 400016China Department of Obstetrics and Gynecology Peking University First HospitalBeijing 100034China Department of Obstetrics and Gynecology Women and Children's Hospital of Chongqing Medical UniversityChongqing 401147China

Intrahepatic cholestasis of pregnancy(ICP)is a significant gestational complication in late pregnancy,potentially leading to severe perinatal complications such as intrauterine fetal demise and preterm *** Obstetrics Group of the Gynecology and Obstetrics Branch and the Perinatal medicine Branch of the chinese Medical Association organized a panel of domestic experts to deliberate and propose recommendations based on domestic and international guidelines,recent evidence-based medical evidence about key clinical issues including risk factors,clinical manifestations,perinatal outcomes,diagnosis,severity grading,maternal and fetal monitoring,treatment methods,timing,and methods of pregnancy termination,and postpartum follow-up for ICP,with the aim to guide its clinical diagnosis,treatment,and management.

关键词： Cholestasis,Intrahepatic Bile Acids Stillbirth Preterm Birth Diagnostic and Therapeutic Guidelines(Theme)

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

学校读者我要写书评

暂无评论

chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical Association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical Association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of chinese Society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese Society of Clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of china Anti-Cancer Association(CACA) chinese Society of Hematology of chinese Medical Association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits medicine Exchange Association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

Stress Echocardiography for Chronic Coronary Syndrome:Clinical Practice Guidelines(2023)

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第5期21卷 475-505页

作者： Peng-Fei ZHANG Jia-Wei TIAN Tian-Gang ZHU Jue-Fei WU Xiao-Ping LENG Yi WANG Meng-Meng LI Xin-Hao LI Qian-Qian WANG Xiao-Peng FENG Jia-Yan LV Li-Xue YIN Yun ZHANG Mei ZHANG chinese Society of Echocardiography,Superficial Tissue and Vascular Group of chinese Society of Ultrasound in medicine,Ultrasound Professional Committee of chinese medicine Education Association State Key Laboratory for Innovation and Transformation of Luobing Theory Key Laboratory of Cardiovascular Remodeling and Function ResearchChinese Ministry of EducationChinese National Health Commission and Chinese Academy of Medical SciencesDepartment of CardiologyQilu Hospital of Shandong UniversityJinanChina The Second Affiliated Hospital of Harbin Medical university HaerbinChina Peking university People's Hospital BeijingChina Sichuan Province People's Hospital ChengduChina Nanfang Hospital Southern Medical UniversityGuangzhouChina Peking Union Medical College Hospital Chinese Academy of Medical SciencesBeijingChina 不详

In the context of the People's Republic of china,coronary artery disease(CAD)presents a sig-nificant clinical challenge,with over 11.3 mil-lion patients ***,the diagnos-is of CAD has predominantly relied on invasive coronary angiography.[1]However,recent advances in clinical research have revealed a notable trend:a substantial 82% of patients subjected to such invas-ive diagnostics do not necessitate interventional therapy.

关键词： coronary clinical patients

中国政治经济学年度发展报告（2023）（下）

在线全文

学校读者我要写书评

暂无评论

政治经济学评论 2024年第3期 90+207-208页

作者： Center for Studies of Contemporary Political Economy,Research Institute for 21st-Century Marxism,Nankai university·university of chinese Academy of Social Science Center for Teaching and Research on Capital,Renmin university of china National Institute of Socialist Political Economy with chinese Characteristics,Renmin university of china 南开大学·中国社会科学院大学21世纪马克思主义研究院当代政治经济学研究中心中国人民大学《资本论》教学与研究中心中国人民大学全国中国特色社会主义政治经济学研究中心

编者按2023年，高质量发展扎实推进，新质生产力加快形成，我国经济总体回升向好，圆满实现发展主要预期目标。为针对性地破解经济恢复发展中的难题，聚焦推进中国式现代化进程中的重点、难点问题，中国政治经济学界开展系统深入研究，...

编者按2023年，高质量发展扎实推进，新质生产力加快形成，我国经济总体回升向好，圆满实现发展主要预期目标。为针对性地破解经济恢复发展中的难题，聚焦推进中国式现代化进程中的重点、难点问题，中国政治经济学界开展系统深入研究，取得系列代表性成果。为准确刻画学界研究进展和轨迹，推动中国经济学理论体系的构建和完善，本刊精选议题如期奉上《中国政治经济学年度发展报告（2023）》。自2010年起，本刊连续十四年发布《中国政治经济学年度发展报告》，“年度发展报告”专栏已成为本刊标志性特色栏目。2023年报告聚焦12个专题，分为（上）（下）两篇，其中专题1—6于报告（上）篇刊登，专题7—12由报告（下）篇刊登。2023年报告（下）选题如下：

关键词：

Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer(2024 edition)

同方期刊数据库人大复印报刊资料评论

在线全文

学校读者我要写书评

暂无评论

Radiation medicine and Protection 2024年第2期5卷 59-67页

作者： Professional Committee of Radiation Oncology china Anti-Cancer Association Branch ofRadiation Oncology chinese Medical Association Branch of Radiation Oncology TreatmentPhysician chinese Medical Doctor Association Qingsong Pang Jun Wang Zhouguang Hui 不详 Tianjin Medical university Cancer Institute&Hospital Tianjin 300060China the Fourth Hospital of Hebei Medical university Shijiazhuang 050011China National Cancer Center National Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China.

Radiotherapy represents an essential treatment approach for esophageal *** recent years,immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with advanced esophageal *** phase III studies on immunotherapy combined with radiotherapy for locally advanced esophageal cancer are currently *** evidence-based medical data are urgently needed to support the integration of immunotherapy and chemoradiotherapy as a new treatment strategy for patients with locally advanced esophageal *** consensus,formulated based on the latest study results,in-depth research,and thorough discussions,provides a comprehensive set of *** document extensively covers treatment strategies and evaluation methods for radiotherapy combined with immunotherapy across patients with operable esophageal cancer,inoperable locally advanced esophageal cancer,and advanced esophageal ***,common complications and radiation-related issues associated with radiotherapy combined with immunotherapy are discussed,serving as clinical *** expert group comprised members from the Professional Committee of Radiation Oncology,china Anti-Cancer Association,the Branch of Radiation Oncology,chinese Medical Association,and the Branch of Radiation Oncology Treatment Physician,chinese Medical Doctor Association.

关键词： Esophageal squamous cell carcinoma Esophageal adenocarcinoma Immunotherapy Chemoradiotherapy Radiotherapy Expert consensus

chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第3期21卷 251-314页

作者： Chang-Sheng MA Shu-Lin WU Shao-Wen LIU Ya-Ling HAN chinese Society of Cardiology chinese Medical Association Heart Rhythm Committee of chinese Society of Biomedical Engineering Beijing Anzhen Hospital Capital Medical University Guandong Provincial People’s Hospital Shanghai First People’s Hospital General Hospital of Northern Theater Command 不详

Atrial fibrillation(AF)is the most common sustained cardiac arrhythmia,significantly impacting patients’quality of life and increasing the risk of death,stroke,heart failure,and *** the past two decades,there have been significant breakthroughs in AF risk prediction and screening,stroke prevention,rhythm control,catheter ablation,and integrated *** this period,the scale,quality,and experience of AF management in china have greatly improved,providing a solid foundation for the development of guidelines for the diagnosis and management of *** further promote standardized AF management,and apply new technologies and concepts to clinical practice in a timely and comprehensive manner,the chinese Society of Cardiology of the chinese Medical Association and the Heart Rhythm Committee of the chinese Society of Biomedical Engineering have jointly developed the chinese Guidelines for the Diagnosis and Management of Atrial *** guidelines have comprehensively elaborated on various aspects of AF management and proposed the CHA2DS2-VASc-60 stroke risk score based on the characteristics of AF in the Asian *** guidelines have also reevaluated the clinical application of AF screening,emphasized the significance of early rhythm control,and highlighted the central role of catheter ablation in rhythm control.

关键词： prevention sustained diagnosis

chinese national clinical practice guidelines on the prevention,diagnosis,and treatment of early gastric cancer

在线全文

学校读者我要写书评

暂无评论

chinese Medical Journal 2024年第8期137卷 887-908页

作者： Peng Li Ziyu Li Enqiang Linghu Jiafu Ji Society of Digestive Endoscopy of the chinese Medical Association Colorectal Surgery Group of the chinese Medical Association chinese Association of Gastroenterologists&Hepatologists National Clinical Research Center for Digestive Diseases chinese Medical Journal Clinical Practice Guideline Collaborative Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China Department of Gastrointestinal Surgery Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Gastroenterology and Hepatology the First Medical CenterChinese People’s Liberation Army General HospitalBeijing 100853China 不详

Background:Gastric cancer is one of the most common malignant tumors in the digestive system in *** comprehensive practice guidelines for early gastric cancer in china are currently ***,we created the chinese national clinical practice guideline for the prevention,diagnosis,and treatment of early gastric ***:This clinical practice guideline(CPG)was developed in accordance with the World Health Organization’s recommended process and with the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)in assessing evidence *** used the Evidence to Decision framework to formulate clinical recommendations to minimize bias and increase transparency in the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and the Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guidelines to ensure completeness and transparency of the ***:This CPG contains 40 recommendations regarding the prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer based on available clinical studies and *** provide recommendations for the timing of Helicobacter pylori eradication,screening populations for early gastric cancer,indications for endoscopic resection and surgical gastrectomy,follow-up interval after treatment,and other ***:This CPG can lead to optimum care for patients and populations by providing up-to-date medical *** intend this CPG for widespread adoption to increase the standard of prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer;thereby,contributing to improving national health care and patient quality of life.

关键词： Early gastric cancer Prevention Screening Diagnosis Treatment Follow-up